Skip to main content

Advertisement

SpringerLink
Log in

Synthesis and Evaluation of Radioiodine-Labeled pH (Low) Insertion Peptide Variant 7-Like Peptide as a Noninvasive Tumor Microenvironment Imaging Agent in a Mouse MDA-MB-231 Triple-Negative Breast Cancer Model

  • Research Article
  • Published:
Molecular Imaging and Biology Aims and scope Submit manuscript

Abstract

Purpose

The pH (low) insertion peptide (pHLIP) family can target the tumor microenvironment (TME). If pHLIP can be labeled with radioiodine, the imaging and treatment of tumors can be considered. However, tyrosine and tryptophan can bind with iodine in the insertion region of pHLIP, and radioiodine labeling may affect the formation of α-helix structures in acidic environments; therefore, it is necessary to adjust the structure of pHLIP. This study aims to develop an 125I-labeled pH (low) insertion peptide variant 7-like peptide (pHLIP (Var7) LP) for imaging the TME in MDA-MB-231 triple-negative breast cancer (TNBC) xenograft tumor models.

Procedures

Based on pHLIP (Var7), a new peptide sequence, pHLIP (Var7) LP, was obtained by the sequence modification method and then characterized. The binding of pHLIP (Var7) LP to MDA-MB-231 cells was analyzed. pHLIP (Var7) LP was labeled with 125I by the iodogen iodination method. Serial biodistribution studies and small-animal single photon emission computed tomography (SPECT)/computed tomography (CT) imaging in subcutaneous MDA-MB-231 TNBC-bearing mice were performed using [125I] I-pHLIP (Var7) LP.

Results

A novel peptide, pHLIP (Var7) LP, has the characteristics of an α-helix structure, electronegativity, and amphiphilicity. Circular dichroism (CD) spectroscopy showed that the peptide presented a typical pH-dependent transition from an unstructured conformation to an α-helix structure when the pH was reduced from 8.0 to 4.0. The relative fluorescence intensities of 5-carboxytetramethylrhodamine (5-TAMRA)-pHLIP(var7) LP at pH = 6.0, 6.6, and 7.4 were 100.00 ± 5.98%, 72.10 ± 4.65%, and 13.72 ± 1.41%, respectively. The distribution of [125I] I-pHLIP (Var7) LP in tumors reached the highest level (8.7 ± 1.6% ID/g) at 2 h after injection, and the tumor-to-muscle ratios and tumor-to-blood ratios increased with time. Of the measured off-target organs, the stomach, kidney, and bladder showed higher uptake levels. SPECT imaging revealed rapid and sustained tumor uptake of [125I] I-pHLIP (Var7) LP in breast cancer-bearing mice.

Conclusions

This study showed that [125I]I-pHLIP (Var7)LP had rapid and sustained tumor uptake in MDA-MB-231 TNBC and provided a new method for TNBC imaging and further treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Pareja F, Reis-Filho JS (2018) Triple-negative breast cancers—a panoply of cancer types. Nat Rev Clin Oncol 15(6):347–348

    Article  CAS  Google Scholar 

  2. Penault-Llorca F, Viale G (2012) Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. Ann Oncol 23(Suppl 6):vi19-22

    Article  Google Scholar 

  3. Aebi S, Davidson T, Gruber G et al (2011) Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):vi12-24

    Article  Google Scholar 

  4. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938–1948

    Article  CAS  Google Scholar 

  5. Jitariu AA, Cîmpean AM, Ribatti D et al (2017) Triple negative breast cancer: the kiss of death. Oncotarget 8(28):46652–46662

    Article  Google Scholar 

  6. Ditsch N, Kolberg-Liedtke C, Friedrich M et al (2021) AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. Breast Care (Basel) 16(3):214–227

    Article  Google Scholar 

  7. Bakker MF, de Lange SV, Pijnappel RM et al (2019) Supplemental MRI screening for women with extremely dense breast tissue. N Engl J Med 381(22):2091–2102

    Article  Google Scholar 

  8. Elghazaly H, Rugo HS, Azim HA et al (2021) Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer. Cancers (Basel) 13(9):2262

    Article  CAS  Google Scholar 

  9. Beusterien K, Grinspan J, Kuchuk I et al (2014) Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects. Oncologist 19(2):127–134

    Article  CAS  Google Scholar 

  10. Liu Z, Jiang L, Liang G et al (2017) Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: a review and meta-analysis of prophylaxis management. J Viral Hepat 24(7):561–572

    Article  CAS  Google Scholar 

  11. Cairns R, Papandreou I, Denko N (2006) Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 4(2):61–70

    Article  CAS  Google Scholar 

  12. Pathak AP, Gimi B, Glunde K et al (2004) Molecular and functional imaging of cancer: advances in MRI and MRS. Methods Enzymol 386:3–60

    CAS  PubMed  Google Scholar 

  13. Penet MF, Glunde K, Jacobs MA et al (2008) Molecular and functional MRI of the tumor microenvironment. J Nucl Med 49(5):687–690

    Article  Google Scholar 

  14. Yu M, Chen Y, Wang Z et al (2020) pHLIP (Var7)-P1AP suppresses tumor cell proliferation in MDA-MB-231 triple-negative breast cancer by targeting protease activated receptor 1. Breast Cancer Res Treat 180(2):379–384

    Article  CAS  Google Scholar 

  15. Chen YH, Yu MM, Wang ZG (2021) Inhibition of MDA-MB-231 cell proliferation by pHLIP (Var7)-P1AP and SPECT imaging of MDA-MB-231 breast cancer-bearing nude mice using 125I-pHLIP (Var7)-P1AP. Nuklearmedizin 60(3):240–248

    Article  Google Scholar 

  16. Yu M, Sun Y, Yang G et al (2021) An experimental study on [125I]I-pHLIP (Var7) for SPECT/CT imaging of an MDA-MB-231 triple-negative breast cancer mouse model by targeting the tumor microenvironment. Mol Imaging 2021:5565932

    Article  Google Scholar 

  17. Tossi A, Sandri L, Giangaspero A (2000) Amphipathic, alpha-helical antimicrobial peptides. Biopolymers 55(1):4–30

    Article  CAS  Google Scholar 

  18. Demoin DW, Wyatt LC, Edwards KJ et al (2016) PET imaging of extracellular pH in tumors with (64) Cu- and (18)F-labeled pHLIP peptides: a structure-activity optimization study. Bioconjug Chem 27(9):2014–2023

    Article  CAS  Google Scholar 

  19. Sosunov EA, Anyukhovsky EP, Sosunov AA et al (2013) pH (low) insertion peptide (pHLIP) targets ischemic myocardium. Proc Natl Acad Sci U S A 110(1):82–86

    Article  CAS  Google Scholar 

  20. Yu M, Zhou H, Liu X et al (2010) Study on biodistribution and imaging of radioiodinated arginine-arginine-leucine peptide in nude mice bearing human prostate carcinoma. Ann Nucl Med 24(1):13–19

    Article  CAS  Google Scholar 

  21. MingMing Yu, Wang RongFu, Yan P et al (2008) Design, synthesis and iodination of an Arg-Arg-Leu peptide for potential use as an imaging agent for human prostate carcinoma. J Label Compd Radiopharm 51(11):374–378

    Article  Google Scholar 

  22. Josefsson M, Grunditz T, Ohlsson T et al (2002) Sodium/iodide-symporter: distribution in different mammals and role in entero-thyroid circulation of iodide. Acta Physiol Scand 175(2):129–137

    Article  CAS  Google Scholar 

  23. Andreev OA, Dupuy AD, Segala M et al (2007) Mechanism and uses of a membrane peptide that targets tumors and other acidic tissues in vivo. Proc Natl Acad Sci U S A 104(19):7893–7898

    Article  CAS  Google Scholar 

  24. Macholl S, Morrison MS, Iveson P et al (2012) In vivo pH imaging with (99m)Tc-pHLIP. Mol Imaging Biol 14(6):725–734

    Article  Google Scholar 

  25. Daumar P, Wanger-Baumann CA, Pillarsetty N et al (2012) Efficient (18)F-labeling of large 37-amino-acid pHLIP peptide analogues and their biological evaluation. Bioconjug Chem 23(8):1557–1566

    Article  CAS  Google Scholar 

Download references

Funding

This study was funded by Shandong Provincial Medical and Health Science and Technology Development Program (Grant No. 202009040347) and the Natural Science Foundation of Shandong Province (Grant No. ZR2021MH038).

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University, No.59, Haier St., Laoshan District, Qingdao, 266100, China

    FengYu Wu, YueHua Chen, DaCheng Li, ZhenGuang Wang & MingMing Yu

Authors
  1. FengYu Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. YueHua Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. DaCheng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. ZhenGuang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. MingMing Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

WFY, CYH, LDC, and WZG performed the experiments and wrote the paper. YMM designed and supervised the research. All authors read and approved the final manuscript.

Corresponding author

Correspondence to MingMing Yu.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, F., Chen, Y., Li, D. et al. Synthesis and Evaluation of Radioiodine-Labeled pH (Low) Insertion Peptide Variant 7-Like Peptide as a Noninvasive Tumor Microenvironment Imaging Agent in a Mouse MDA-MB-231 Triple-Negative Breast Cancer Model. Mol Imaging Biol 24, 570–579 (2022). https://doi.org/10.1007/s11307-021-01702-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11307-021-01702-0

Key words

Search

Navigation